Zealand Pharma slumps, analysts point to rival trial data

Roche Bobois SA

06/11/2025 13:18

** Shares in Danish biotechnology company Zealand Pharma ZELA.CO reverse course in afternoon trade and fall 9% after Eli Lilly's LLY.N amylin trial data

** Lilly's experimental obesity drug helped patients lose as much as 20.1% of their weight in a mid-stage trial, the US pharmaceutical company said in a statement

** Nordnet analyst Per Hansen says this potentially puts pressure on Zealand and its upcoming research data from the petrilintide collaboration with Roche RBO.PA

** Jefferies says it remains confident ZEAL/Roche's amylin will also deliver 15%-20% weight loss longer-term

** "...but with Phase IIb data not until 1H26E and c.6 months behind obesity juggernaut LLY, we acknowledge it is difficult to push a best-in-class narrative until we have more comparable data," the brokerage adds

** Petrelintide belongs to a class of drugs known as long-acting amylin analogues, which mimic a hormone called amylin that is co-secreted with insulin

** The stock is on track for its worst day since April

 (Reporting by Izabela Niemiec)

 ((izabela.niemiec@thomsonreuters.com))